- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Visual adaptation.
Displaying page 1 of 1.
EudraCT Number: 2007-003249-34 | Sponsor Protocol Number: F13640GE209 | Start Date*: 2007-09-24 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinationa... | |||||||||||||
Medical condition: Patients who have failed adaptation of opioid therapy for cancer pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000972-15 | Sponsor Protocol Number: 1002 | Start Date*: 2004-09-03 |
Sponsor Name:Michael Larsen | ||
Full Title: DIAMETIB | ||
Medical condition: Diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002696-10 | Sponsor Protocol Number: CCPK850X2202 | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa c... | |||||||||||||
Medical condition: retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005601-22 | Sponsor Protocol Number: poc1doxy | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ... | |||||||||||||
Medical condition: Diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002588-17 | Sponsor Protocol Number: SAM-IIT01 | Start Date*: 2019-10-21 |
Sponsor Name:Universitätsklinikum Tübingen | ||
Full Title: Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents | ||
Medical condition: Myopia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003253-36 | Sponsor Protocol Number: LBS-008-CT03 | Start Date*: Information not available in EudraCT |
Sponsor Name:Belite Bio, Inc | ||
Full Title: Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects | ||
Medical condition: Stargardt Disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021139-15 | Sponsor Protocol Number: ESC-928-MOL-0000-I | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Technische Universität München Fakultät für Medizin | |||||||||||||
Full Title: Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors? | |||||||||||||
Medical condition: This study tests the hypothesis that the Radiation dose escalation to the macroscopic Tumor improves the locoregional control survival after concomitant chemoradiation over 2 years. As a transla... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004214-42 | Sponsor Protocol Number: RETIRD02 | Start Date*: 2012-09-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due ... | ||||||||||||||||||
Medical condition: Leber Congenital Amaurosis Retinitis pigmentosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004000-33 | Sponsor Protocol Number: INZ701-201 | Start Date*: 2021-06-10 | |||||||||||
Sponsor Name:Inozyme Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i... | |||||||||||||
Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004039-10 | Sponsor Protocol Number: NL81112.041.22 | Start Date*: 2022-06-24 | |||||||||||
Sponsor Name:UMC Utrecht - Van Creveldkliniek | |||||||||||||
Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study | |||||||||||||
Medical condition: Congenital hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004546-15 | Sponsor Protocol Number: 12-PP-12 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Nice | |||||||||||||
Full Title: Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up | |||||||||||||
Medical condition: severe behavioral disorders in mental retardation, autistic syndromes schizophrenia psychosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
